Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Pellegrino Musto, Roberta Della Pepa et al.|Haematologica|2023Cited by 19
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Pellegrino Musto, Salvatore Palmieri et al.|Hematological Oncology|2024Cited by 7
Multiple Myeloma in Italy: An Epidemiological Model by Treatment Line and Refractoriness StatusRoberto Mina, Stefania Bellucci, Silvia Mangiacavalli et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 5